


Algeria

Human Papillomavirus and Related Cancers, Fact Sheet 2017 (2017-04-19)



I. Key data on HPV and HPV-related cancers



Algeria has a population of 14.14 millions women ages 15 years and older who are at risk of developing cervical cancer. Current estimates indicate that every year 1288 women are diagnosed with cervical cancer and 510 die from

the disease. Cervical cancer ranks as the 3rd most frequent cancer among women in Algeria and the 9th most frequent cancer among women between 15 and 44 years of age. About 2.1% of women in the general population are estimated to harbour cervical HPV-16/18 infection at a given time, and 76.8% of invasive cervical cancers are attributed to HPVs 16 or 18.

Table 1. Crude incidence rates of HPV-related cancers

	Male	Female
Cervical cancer	-	7.1
Anal cancer	0.2	0.0
Vulva cancer	-	0.1
Vaginal cancer	-	0.1
Penile cancer	0.0	-
Pharynx (excluding nasopharynx)	0.5	0.4


Table 2. Burden of cervical cancer

	Incidence	Mortality
Annual number of new cases/deaths	1288	510
Crude rate	7.1	2.8
Age-standardized rate	8.5	3.5
Cumulative risk 0-74 years (%)	1.0	0.4
Ranking of cervical cancer (all years)	3rd	6th
Ranking of cervical cancer (15-44 years)	9th	12th

Table 3. Burden of cervical HPV infection Algeria

	No. Tested	% (95% CI)
HPV prevalence in women with normal cytology	865	6.1 (4.7-7.9)
HPV 16/18 prevalence:		
Normal cytology	865	2.1 (1.3-3.3)
Low-grade cervical lesions	-	--
High-grade cervical lesions	-	--
Cervical cancer	181	76.8 (70.1-82.3)

Figure 1. Comparison of the ten most frequent HPV oncogenic types in Algeria among women with and without cervical lesions



*No data available. No more types than shown were tested or were positive.

Algeria

Human Papillomavirus and Related Cancers, Fact Sheet 2017 (2017-04-19)



II. Complementary data on cervical cancer prevention

Table 4. Factors contributing to cervical cancer (co-factors)

Smoking prevalence (%), women	-
Total fertility rate (live births per women)	2.7
Hormonal contraception use (%) (pill, injectable or implant), among women	45.9
HIV prevalence (%), adults (15-49 years)	<0.1 [<0.1 - <0.1]

Table 5. Sexual behaviour

MEN	
Percentage of 15-year-old who have had sexual intercourse	-
Range of median age at first sexual intercourse	-
WOMEN	
Percentage of 15-year-old who have had sexual intercourse	-
Range of median age at first sexual intercourse	-


Table 6. HPV vaccine introduction

HPV vaccination programme	No Program
Date of HPV vaccination routine immunization programme start	-
HPV vaccination target age for routine immunization	-
Full course HPV vaccination coverage for routine immunization:	
% (calendar year)	-

Table 7. Cervical screening practices and recommendations

Cervical cancer screening coverage, % (age and screening interval, reference)	2.0% (All women aged 25-65 screened every 3y, Sancho-Garnier 2013)
Screening ages (years)	25/30-60/65
Screening interval (years) or frequency of screens	3 Years

Figure 2. Estimated coverage of cervical cancer screening in Algeria, by age and study



Contact information:

ICO HPV Information Centre
 Institut Català d'Oncologia
 Avda. Gran Via de l'Hospitalet, 199-203
 08908 L'Hospitalet de Llobregat (Barcelona, Spain)
 e-mail: info@hpvcentre.net
 internet adress: www.hpvcentre.net